HRC - Hill-Rom limits comments on recent Bardy deal on reimbursement issues

Hill-Rom Holdings (HRC) earlier declined to say much about its recent planned purchase of Bardy Diagnostics after Novitas last month announced category 1 reimbursement rates that analysts said were well below current rates.Recall that Bardy competitor iRhythm (IRTC) declined 33% in one day after the Novitas news was released on Holter monitor device.Hill-Rom CFO Barbara Bodem on the earnings conference call said that Bardy acquisition is not included in the company's updated revenue guidance.CEO John Groetelaars said that the company is monitoring the reimbursement situation "closely" and said he wanted to limit further comment as it's a "sensitive" period of time in light of some pending talks that will take place."And for that reason, I don’t think it’s productive to have speculative comments and read into it too much," Groetelaars said on the call.Recall Feb. 3, iRhythm fade continues as competitor talks about reimbursement issues.

For further details see:

Hill-Rom limits comments on recent Bardy deal on reimbursement issues